Mergers & Acquisitions ·
Harrow, Inc. entered into an Asset Purchase Agreement with Viatris Inc. to acquire the global rights to TYRVAYA®, a…
HROWMHarrow, Inc.
Harrow, Inc. entered into an Asset Purchase Agreement with Viatris Inc. to acquire the global rights to TYRVAYA®, a cholinergic agonist nasal spray for dry eye disease. Harrow will pay $30 million in cash at closing and up to $70 million in contingent milestone payments based on annual net sales, totaling potential consideration of $100 million. The company expects to fund the upfront payment with existing cash reserves. The transaction is anticipated to close in the second half of 2026, subject to customary conditions. Harrow, Inc. operates in the pharmaceutical industry, providing ophthalmic disease management solutions.